NAB-paclitaxel as third-line therapy after failure of gemcitabine and 5-fluorouracil (5-FU) based combinations in advanced gall bladder cancer patients

被引：0
|
作者：
Goel, V. [1 ]
Talwar, V. [1 ]
Patnaik, N. [2 ]
Raina, S. [1 ]
Singh, S. [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Med Oncol, New Delhi, India
[2] UCMS & GTB Hosp, Pathol, Delhi, India
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
241P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] NAB-PACLITAXEL as third-line therapy after failure of gemcitabine and 5-FU based combinations in advanced gall bladder cancer patients
    Manana, S. Singh
    Goel, V.
    Talwar, V.
    Raina, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Efficacy of nab-paclitaxel on 5-fluorouracil (5-FU) resistant human gastric cancer cell lines
    Nukatsuka, Mamoru
    Kobunai, Takashi
    Matsuoka, Kazuaki
    Takechi, Teiji
    CANCER RESEARCH, 2014, 74 (19)
  • [3] Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma
    McNulty, M.
    Dean, A.
    Das, A.
    Gordon, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
    Pfeiffer, P.
    Nielsen, D.
    Bjerregaard, J.
    Qvortrup, C.
    Yilmaz, M.
    Jensen, B.
    ANNALS OF ONCOLOGY, 2008, 19 (06) : 1141 - 1145
  • [5] Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer
    Talwar, Vineet
    Raina, Shubhra
    Goel, Varun
    Dash, Prasanta
    Doval, Dinesh C.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2020, 152 (05) : 475 - 481
  • [6] Gemcitabine and Protracted 5-Fluorouracil Infusion as Third-line Chemotherapy in Refractory Colorectal Cancer Patients
    Bitossi, Raffaella
    Sculli, Carla Maria
    Tampellini, Marco
    Alabiso, Irene
    Brizzi, Maria Pia
    Ferrero, Anna
    Ottone, Azzurra
    Bellini, Elisa
    Gorzegno, Gabriella
    Berruti, Alfredo
    Dogliotti, Luigi
    ANTICANCER RESEARCH, 2008, 28 (5B) : 3055 - 3060
  • [7] Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma.
    Dean, Andrew Peter
    Das, Adarsh
    McNulty, Meabh
    Higgs, Domenic
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
  • [9] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [10] FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
    Matsumoto, Toshihiko
    Kurioka, Yusuke
    Okazaki, Ukyo
    Matsuo, Yu
    Kimura, Shogo
    Miura, Kou
    Tsuduki, Takao
    Takagi, Shinjiro
    Takatani, Masahiro
    Morishita, Hirofumi
    PANCREAS, 2020, 49 (04) : 574 - 578
12345